Literature DB >> 9219272

Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.

D J Drucker1, Q Shi, A Crivici, M Sumner-Smith, W Tavares, M Hill, L DeForest, S Cooper, P L Brubaker.   

Abstract

Species-specific differences in the enzymatic inactivation of peptides is an important consideration in the evaluation of therapeutic efficacy. We demonstrate that glucagon-like peptide 2 (GLP-2), shown to be highly intestinotrophic in mice, promotes an increase in intestinal villus height but has no trophic effect on small bowel weight in rats. The reduced intestinotrophic activity of GLP-2 in rats is attributable to inactivation by the enzyme dipeptidyl peptidase IV (DPP-IV). GLP-2(1-33) was degraded to GLP-2(3-33) following incubation with human placental DPP-IV or rat serum but not by serum from DPP-IV-deficient rats. Administration of rat GLP-2 to DPP-IV-deficient rats was associated with markedly increased bioactivity of rat GLP-2 resulting in a significant increase in small bowel weight. A synthetic GLP-2 analog, r[Gly2]GLP-2, with an alanine to glycine substitution at position 2, was resistant to cleavage by both DPP-IV and rat serum in vitro. Treatment of wild-type rats with r[Gly2]GLP-2 produced a statistically significant increase in small bowel mass. DPP-IV-mediated inactivation of GLP-2 is a critical determinant of the growth factor-like properties of GLP-2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219272     DOI: 10.1038/nbt0797-673

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  42 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 2.  The use of hormonal growth factors in the treatment of patients with short-bowel syndrome.

Authors:  Palle B Jeppesen
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Enhancing bowel adaptation in short bowel syndrome.

Authors:  Palle Bekker Jeppesen; Per Brobech Mortensen
Journal:  Curr Gastroenterol Rep       Date:  2002-08

4.  Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders.

Authors:  Daniel J Drucker
Journal:  CMAJ       Date:  2012-01-23       Impact factor: 8.262

Review 5.  The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective.

Authors:  Palle Bekker Jeppesen
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

Review 6.  Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Authors:  Jean Debédat; Chloé Amouyal; Judith Aron-Wisnewsky; Karine Clément
Journal:  Semin Immunopathol       Date:  2019-04-25       Impact factor: 9.623

7.  Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats.

Authors:  M A Ghatei; R A Goodlad; S Taheri; N Mandir; A E Brynes; M Jordinson; S R Bloom
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

Review 8.  Discovery, characterization, and clinical development of the glucagon-like peptides.

Authors:  Daniel J Drucker; Joel F Habener; Jens Juul Holst
Journal:  J Clin Invest       Date:  2017-12-01       Impact factor: 14.808

Review 9.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

Review 10.  Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Authors:  Magnus F Grøndahl; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.